Ginsenoside Rg3 Decreases Fibrotic and Invasive Nature of Endometriosis by Modulating miRNA-27b: In Vitro and In Vivo Studies by 源�誘쇨꼍 et al.
1SCientiFiC RepoRtS | 7: 17670  | DOI:10.1038/s41598-017-17956-0
www.nature.com/scientificreports
Ginsenoside Rg3 Decreases 
Fibrotic and Invasive Nature of 
Endometriosis by Modulating 
miRNA-27b: In Vitro and In Vivo 
Studies
Min Kyoung Kim  1,2,3, Seung Kyun Lee2,4, Ji Hyun Park2,4, Jae Hoon Lee 1,2, Bo Hyon Yun 1,2, 
Joo Hyun Park2,4, Seok Kyo Seo 1,2, SiHyun Cho  2,4 & Young Sik Choi 1,2
This research aimed to evaluate the potential therapeutic effects of Rg3 on endometriosis and identify 
target miRNAs. We designed an in vitro study using human endometrial stromal cells (HESCs) obtained 
from patients with endometriosis and an in vivo study using mouse models. HESCs were treated with 
Rg3-enhanced red ginseng extract (Rg3E); real-time PCR and microarray profiling, transfection, and 
western blot were performed. Mouse endometriosis models were developed and supplemented with 
Rg3E for 8 weeks. Gross lesion size and fibrotic character were analyzed in the mouse models. RNA 
levels of Ki-67, col-1, CTGF, fibronectin, TGF-β1, MMP2 and MMP9 significantly decreased in HESCs 
after Rg3E treatment. Microarray analysis revealed downregulation of miR-27b-3p, which is related 
to fibrosis modulation. Expression of miR-27b-3p was significantly higher in HESCs from patients 
with endometriosis than that of controls, and Rg3E treatment significantly decreased its expression; 
the contraction and migration assay revealed significant reductions in both fibrosis and migration 
potential in Rg3E-treated HESCs from endometriosis patients. A decrease in size and fibrotic character 
of endometrial lesions from the Rg3E groups was observed in vivo. In conclusion, Rg3 effectively altered 
fibrotic properties of HESCs from patients with endometriosis, which is likely associated with miR-
27b-3p modulation.
Endometriosis is a common benign gynecological disorder, affecting up to 10% of all women of reproductive age 
and 20–50% of women with chronic pelvic pain and/or infertility1. It is defined as the proliferation of endometrial 
tissue outside of the uterine cavity2. The exact pathogenic mechanisms of endometriosis are not known and diag-
nosis is often delayed—making it more difficult to treat, both medically and surgically. However, several studies 
demonstrate that endometriosis has an invasive and fibrotic nature that is induced by inflammation3,4, which may 
represent a key pathophysiological target for treatment.
MicroRNAs (miRNAs) are a family of endogenous, small, noncoding, functional RNAs that control gene 
expression by translational repression or degradation of messenger RNA transcripts after targeting the 
3′-untranslated region (3′-UTR)5. Several studies have demonstrated that miRNAs are important regulators of 
development and cellular homeostasis through their control of diverse biological processes. Aberrant miRNA 
expression is known to be associated with various human diseases such as cancer, cardiovascular and inflamma-
tory disorders, as well as gynecological diseases6–10. Previously, we showed that several circulating miRNAs such 
as let-7b, 7d, and 7 f are differentially expressed in the sera of endometriosis patients5. Several other studies also 
identified differential expression of miRNAs in eutopic and ectopic endometrial samples from endometriosis 
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patients using microarray profiling11–13. It has been suggested that miRNAs act as potent regulators of gene 
expression in the pathogenesis of endometriosis and its associated reproductive disorders14.
Korean red ginseng (KRG) has been traditionally used as an herbal medicine to treat various diseases in 
Eastern Asia. Recent studies have shown that KRG has various biological activities such as immune enhance-
ment, antioxidant, anti-inflammatory, neuroprotective, anti-metabolic syndrome, and anti-menopausal dis-
order effects15–19. Ginsenosides are biologically active components of KRG, and there are many different types 
of ginsenosides with different pharmacological activities20. Ginsenoside Rg3 is a major active component of 
KRG and has been shown to have various pharmacological benefits such as immunomodulatory, antioxidant, 
anti-inflammatory, anticancer, and anti-aging activities in several diseases and infections21,22. Previous studies 
demonstrated that Rg3-enhanced red ginseng extract (Rg3E) has anti-inflammatory effects in asthmatic lung 
tissue, brain, hepatic and renal injury23–25. Also, many types of ginsenosides were studied to be associated with 
fibrosis. Ginsenoside Rh2 improved cardiac fibrosis by increasing PPARδ signaling26. Ginsenoside Rg1 was shown 
to reduce cigarette smoke-induced airway fibrosis by inhibiting TGF-β/Smad pathway in a rat model27. Rg3 was 
also revealed to be anti-fibrotic in hepatic fibrosis of mouse model28. Considering the anti-inflammatory and 
anti-fibrotic activity of ginsenosides, we hypothesized that Rg3E effectively inhibits the key pathophysiology of 
endometriosis.
Matsuzaki et al. described the fibrosis in endometriosis is induced by the Wnt/β-catenin signaling pathway29. 
Treating the endometrial stromal cells of endometriosis patients with antagonists of Tcf/β-catenin complexes 
significantly decreased the expression of fibrotic markers such as α-smooth muscle actin, type I collagen (Col-1), 
connective tissue growth factor (CTGF), and fibronectin. They also revealed that inhibiting aberrant activation 
of Wnt/β-catenin signaling also results in hindering cell proliferation, migration, and/or invasion of endometrial 
stromal cells of patients with endometriosis30. Therefore, we hypothesized that Rg3E may also have the potential 
to inhibit the Wnt/β-catenin signaling pathway to decrease the cellular fibrosis, proliferation, and/or invasion of 
endometrial stromal cells.
The objective of this study was to investigate whether Rg3E affects the key pathological processes of endome-
triosis such as invasion, proliferation, and fibrosis in vitro and in vivo. Additionally, we analyzed the role of miR-
NAs in a pathogenic condition previously described31 and evaluated the therapeutic effects of Rg3E by targeting 
specific miRNAs found from the analysis.
Results
Patient Characteristics. There were no significant differences in age and body mass index (BMI) between 
the endometriosis group and controls. However, the endometriosis group had significantly lower gravidity 
(0.64 ± 0.34 vs. 2.18 ± 0.50, P = 0.019) and parity (0.45 ± 0.25 vs. 1.36 ± 0.28, P = 0.024) than those of the con-
trols, and serum CA-125 levels were significantly higher than those of the controls (69.18 ± 17.56 vs. 15.14 ± 2.90, 
P = 0.015) (Table 1).
Effects of Rg3E on Cell Proliferation, Invasion, Apoptosis, and Fibrosis Markers. The MTT 
assay, used to test the toxicity of Rg3E at concentrations of 0, 400, 800, 1200, and 1600 µg/mL, showed signif-
icant decreases in cell viability at 800 µg/mL. Therefore, 400 µg/mL Rg3E was used for all subsequent experi-
ments (Supplementary Information). Ki67, a cell proliferation marker, showed significantly decreased level in 
Rg3E-treated human endometrial stromal cells (HESCs) (0.5 fold decrease, P = 0.005); however, no significant 
changes were observed in Ishikawa cells (0.62 fold decrease, P = 0.213). Levels of matrix metalloproteinase 
(MMP)-2 and MMP9, markers of invasion, significantly decreased in Rg3E-treated HESCs (1.0 vs. 0.36, P = 0.002 
in MMP2; 1.0 vs. 0.53, P = 0.014 in MMP9) and Ishikawa cells (0.16 fold decrease, P = 0.001 in MMP2; 0.17 fold 
decrease, P = 0.004 in MMP9). In contrast, caspase 3, a marker of apoptosis, was not significantly changed in 
either the Ishikawa cells (1.37 fold increase, P = 0.514) or HESCs (2.07 fold increase, P = 0.118) after Rg3E treat-
ment. Markers of fibrosis, including type 1 collagen (Col-1) (0.24 fold decrease, P = 0.002 in HESCs; 0.25 fold 
decrease, P = 0.012 in Ishikawa cells), connective tissue growth factor (CTGF) (0.3 fold decrease, P < 0.001 in 
HESCs; 0.67 fold decrease, P = 0.031 in Ishikawa cells), fibronectin (0.25 fold decrease, P = 0.002), and transform-
ing growth factor (TGF)-β1 (0.32 fold decrease, P = 0.013) showed significantly decreased levels after treatment 
with Rg3E in HESCs (Fig. 1).
Effects of Rg3E on Cell Migration and Collagen Gel Contraction. The migration assay showed 
a significant decrease in cell number after Rg3E treatment for both Ishikawa cells (cell count: 71.75 vs. 14.15, 
P = 0.003, N = 7) and HESCs (cell count: 27.61 vs. 12.62, P = 0.026, N = 12) (Fig. 2(a,b)). Collagen gel contractil-
ity of HESCs was evaluated using the collagen gel contraction assay. After treatment with Rg3E for 72 h, collagen 
gel contraction was significantly less than that of the control group that did not receive Rg3E treatment (contrac-
tion gel diameter: 10.42 vs. 12.17, P = 0.012, N = 6) (Fig. 2(c)).
Control (N = 15) Endometriosis (N = 21) P-value
Age (years) 36.09 ± 1.97 33.91 ± 2.33 0.482
Gravida 2.18 ± 0.50 0.64 ± 0.34 0.019
Parity 1.36 ± 0.28 0.45 ± 0.25 0.024
BMI (kg/m2) 22.16 ± 0.74 20.27 ± 0.63 0.065
CA125 (IU/ml) 15.14 ± 2.90 69.18 ± 17.56 0.015
Table 1. Patient characteristics. #The data were expressed in mean ± SEM.
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miRNA Profiling after Rg3E Treatment and Validation of miR-27b-3p in Endometriosis. To 
evaluate the effects of Rg3E on miRNAs associated with endometriosis, miRNA profiling was performed after 
Rg3E treatment of HESCs from patients with endometriosis. MicroRNA microarray analysis of samples from 
patients with endometriosis revealed several upregulated miRNAs. After Rg3E treatment, 20 miRNAs were sig-
nificantly upregulated more than two-fold and six miRNAs were significantly downregulated more than two-fold; 
miR-27b-3p was one of the most downregulated miRNAs after Rg3E treatment in HESCs from patients with 
endometriosis. The miR-27b-3p is specifically related to fibrosis and is an important characteristic of endometri-
osis. To validate the miRNA microarray results, expression levels of miR-27b-3p were compared between eutopic 
endometria from patients with endometriosis and those without the disease. In the eutopic endometrium of 
patients with endometriosis, miR-27b-3p expression was approximately two-fold higher than that observed in 
patients without the disease (fold change 0.28 vs. 0.15, P = 0.004) (Fig. 3). After Rg3E treatment, miR-27b-3p 
expression significantly decreased in HESCs (0.51 fold decrease, P = 0.029) (Fig. 4(b), Table 2); however, similar 
changes were not observed in Ishikawa cells.
miR-27b-3p Inhibitor Transfection and Western Blot. To evaluate transfection efficacy, miR-27b-3p 
expression was measured 48 h after transfection with an hsa-miR-negative control and hsa-miR-27b-3p inhib-
itor in HESCs from the endometrium of the patients with endometriosis. Expression of miR-27b-3p was 100- 
to 200-fold lower after treatment with the hsa-miR-27b-3p inhibitor than that observed after treatment with 
the hsa-miR-negative control (Supplementary data). Transfection of the miR-27b-3p inhibitor downregulated 
Figure 1. mRNA concentrations of Ki-67, MMP2, MMP9, Caspase 3 and fibrosis markers after Rg3E treatment 
in Ishikawa cells and HESCs in patients with endometriosis. Both types of cells were treated with Rg3E for 48 h 
before analysis. Quantitative real-time polymerase chain reaction (qRT-PCR) amplification was performed 
using the 7300 Real Time PCR System (Applied Biosystems, Foster City, CA, USA). The mRNA concentrations 
of each sample were normalized to GAPDH expression. (a) Ki-67 was significantly decreased in HESCs after 
Rg3E treatment. Decreasing trend was noted in Ishikawa cells without statistical significance. (b) MMP2 and (c) 
MMP9 were significantly downregulated in both Ishikawa cells and HESCs. (d) Caspase 3 showed increasing 
trend without statistical significance in both Ishikawa cells and HESCs. The fibrosis markers, (e) Col-1 (f) CTGF 
(g) fibronectin and (h) TGF-β1 were all significantly decreased in HESCs. (*P < 0.05. **P < 0.01. N = 8).
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Figure 2. Migration assay of (a) Ishikawa cells and (b) HESCs of the patients with endometriosis after 
48h-Rg3E treatment and (c) Contraction gel assays of HESCs of the patients with endometriosis before and 
after 72 hours of Rg3E treatment. (*P < 0.05. **P < 0.01). (a,b) Migration assays in Ishikawa cells (cell count: 
71.75 vs. 14.15, P = 0.003, N = 7) and HESCs (cell count: 27.61 vs. 12.62, P = 0.026, N = 12) of patients with 
endometriosis showed significantly decreased cell count. (c) Collagen gel contraction assay after 72 hours of 
Rg3E treatment revealed significantly less collagen gel contraction compared to the control group. (Collagen 
gel diameter (mm): 12.17 vs. 10.42, P = 0.012, N = 6) (Rg3E−: without Rg3E treatment; Rg3E+: with Rg3E 
treatment; BDM: 3-Butandione manaxime treatment).
www.nature.com/scientificreports/
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markers of fibrosis in HESCs (Fig. 5). Col-1 mRNA concentration and protein expression significantly decreased 
after treatment with the miR-27b-3p inhibitor (0.40 fold decrease, P = 0.035), whereas that of CTGF (1.02 fold 
increase, P = 0.979), fibronectin (0.45 fold decrease, P = 0.063), and TGF-β1 (0.45 fold decrease, P = 0.057) did 
not significantly change. MMP2 and MMP9, markers of invasion, were also affected by transfection of the miR-
27b-3p inhibitor. Both mRNA concentration and protein expression of MMP9 were significantly downregulated 
(0.40 fold decrease, P = 0.035), and those of MMP2 also decreased; however, the results for MMP2 were not 
significant.
Mouse Model of Endometriosis. After 8 weeks of Rg3E treatment, the mice were sacrificed and their 
endometriotic lesions were obtained. All transplanted endometriotic lesions were found in the peritoneum of 
the sacrificed mice. The mean diameter of lesions in the vehicle, low-dose, and high-dose groups was 6.55 mm, 
5.25 mm, and 4.88 mm, respectively. The average implant size in each group decreased as the dose of Rg3E was 
increased (Fig. 6(a–c)). Lesions from the treatment groups were significantly smaller than those from the vehicle 
group (vehicle vs. low dose, P = 0.007, vehicle vs. high dose, P = 0.006, N = 10 per group). However, no significant 
differences were noted between treatment groups.
Endometriotic lesions were stained with Masson’s trichrome stain, and mean staining scores were calculated. 
Similar to the results observed for lesion size, mean staining scores for implants from each group decreased as the 
dose of Rg3E was increased. Mean staining scores of the vehicle, low-dose, and high-dose groups were 5.45, 4.36, 
Figure 3. Expressions of miR-27b-3p in eutopic endometrium of the patients with and without endometriosis. 
The Affymetrix GeneChip® miRNA array process was conducted per the manufacturer’s protocol. A 
comparative analysis between test and control samples was carried out using fold-change. The basal miR-27b-3p 
expression was significantly increased in endometriosis patients compared to control. (*P < 0.05. **P < 0.01. 
N = 10).
Figure 4. Expressions of miR-27b-3p in (a) Ishikawa cell lines and (b) HESCs from the patients with 
endometriosis after Rg3E treatment. Both types of cells were treated with Rg3E for 48 h before microarray 
analysis. The Affymetrix GeneChip® miRNA array process was conducted per the manufacturer’s protocol. 
A comparative analysis between test and control samples was carried out using fold-change. The miR-27b-3p 
expression was significantly downregulated in endometriosis patient’s HESCs after Rg3E treatment. MiR-
27b-3p is known for its correlation with fibrosis and its downregulation by Rg3E demonstrates the possibility of 
Rg3E decreasing fibrotic nature of endometriosis. (*P < 0.05. N = 6).
www.nature.com/scientificreports/
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and 4.18, respectively. Treatment group scores were significantly smaller than those of the vehicle group (vehicle 
vs. low dose, P = 0.006, vehicle vs. high dose, P = 0.011) (Fig. 6(d,e)).
In vivo mRNA concentrations of the invasion and fibrosis markers were examined by qRT-PCR. Similar to the 
in vitro study results, MMP2, MMP9, CTGF, Col-1, fibronectin and TGF-β1 were all significantly downregulated 
in mice with 8-weeks of Rg3E treatment compared to control mice (Fig. 7).
Discussion
This study demonstrates that Rg3E from KRG significantly alters several major pathogenic characteristics of endo-
metriosis, both in vitro and in vivo. To our knowledge, this report is the first study to evaluate the effects of Rg3E on 
endometriosis. The treatment mechanism involved changes in several miRNAs, including miR-27b-3p. In this study, 
we show that miR-27b-3p expression is elevated in the eutopic endometrium of patients with endometriosis, and Rg3E 
effectively reduces expression of this miRNA in HESCs from patients with endometriosis. Modulation of miR-27b-3p 
is associated with alteration of several cellular characteristics of endometriosis, including cell proliferation and invasion. 
Among these changes, the most profound effect was seen in fibrosis formation. We showed that Rg3E and miR-27b-3p 
inhibition effectively reduce endometriosis fibrotic potential using a contraction gel assay and an in vivo mouse model.
Endometriosis is considered a benign disease; however, it often presents characteristics of malignancy such as 
proliferation and invasion32, and previous studies have shown that Rg3 inhibits such characteristics. A Chinese 
study demonstrated that Rg3 stimulates apoptosis and exhibits antitumor activity against lung cancer cells in 
vitro22. Rg3 is also known to suppress pro-angiogenic (TNF-α) and immunosuppressive cytokine (TGF-β) secre-
tion, which may promote Rg3-induced immunogenic tumor cell death33. The invasive properties of endometrio-
sis are related to an increase in proteolytic activity and matrix remodeling. MMPs are important for degrading the 
extracellular matrix, which takes part in endometriosis development34. This study shows that Rg3E significantly 
downregulates MMP2 and MMP9, blocking a significant pathogenic pathway of endometriosis.
The most interesting point of this study is inhibition of fibrosis by Rg3E. Fibrosis is also an important patho-
genic characteristic of endometriosis that aggravates infertility and pelvic pain. A previous study demonstrated 
that the Wnt/β-catenin signaling pathway is involved in regulating the cellular and molecular mechanisms of 
fibrosis in endometriosis, and the Tcf/β-catenin complex decreases fibrotic markers29. Another recent study 
claimed that endometriotic mesenchymal stem cells significantly promote fibrogenesis in ovarian endometri-
oma by paracrine production of TGF-β1 and Wnt135. A study using TGF- β1 knock-out mice also has shown 
that TGF- β1 deficiency suppresses endometriotic lesion development, which emphasizes the role of TGF- β1 in 
endometriosis36. The present study shows Rg3E’s anti-fibrotic effects in HESC-culture experiments and a collagen 
gel contraction assay, as well as fibrosis-related miRNA transfection. Previously, only one animal study reported 
the relationship between Rg3 and fibrosis, showing that Rg3 inhibits hepatic fibrosis in murine Schistosomiasis 
japonica models28. In this study, Rg3E greatly decreased expression of all the fibrosis-related markers that we 
Up-regulated Down-regulated
miRNA FC P-value miRNA FC P-value
hsa-miR-3188 3.121276 0.030 hsa-miR-22-5p −7.511362 0.011
hsa-miR-4674 3.102003 0.049 hsa-miR-154-5p −3.965245 0.009
hsa-miR-6805-5p 2.813756 0.026 hsa-miR-654-3p −2.518972 0.041
hsa-miR-4516 2.734496 0.030 hsa-miR-27b-3p −2.454641 0.029
hsa-miR-6765-5p 2.675679 0.041 hsa-miR-28-3p −2.216515 0.049
hsa-miR-8089 2.599531 0.046 hsa-miR-140-5p −2.207144 0.033
hsa-miR-6821-5p 2.59466 0.044
hsa-miR-3621 2.545324 0.034
hsa-miR-4649-5p 2.539717 0.0001
hsa-miR-1908-5p 2.488741 0.048
hsa-miR-4486 2.44996 0.033
hsa-miR-8069 2.369964 0.034
hsa-miR-663a 2.33128 0.035
hsa-miR-6781-5p 2.241129 0.026
hsa-miR-4690-5p 2.17942 0.035
hsa-miR-6729-5p 2.146922 0.029
hsa-miR-149-3p 2.140209 0.027
hsa-miR-6125 2.111751 0.031
hsa-miR-4745-5p 2.092432 0.047
hsa-miR-937-5p 2.086316 0.038
Table 2. Microarray analysis and significant fold changes of miRNAs before and after 48h-Rg3E treatment 
in HESCs of patients with endometriosis. There were six significantly decreased miRNAs and miR-27b-3p 
(previously reported to be associated with modulating fibrosis) was included. Functions of other decreased 
miRNAs were yet to be discovered or unrelated to the major pathogenic characteristics of endometriosis. 
Additionally, there were twenty miRNAs that were significantly increased after Rg3E treatment. However, these 
miRNAs’ roles were not yet clarified. #FC: fold change. FC > 2 and P < 0.05 were considered significant.
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Figure 5. mRNA concentrations and protein expressions of Col-1, CTGF, Fibronectin, TGF-β1, MMP2 and 
MMP9 in HESCs from the patients with endometriosis after mir-27b-3p inhibitor transfection. Cells were 
transfected with miR-27b-3p inhibitor for 48 h, and then subjected to qRT-PCR and western blot analysis to 
determine the mRNA concentrations and protein expression levels of Col-1, CTGF, Fibronectin, TGF-β1, 
MMP2 and MMP9. The mRNA concentrations and protein expressions of (a) Col-1 was significantly decreased. 
(b) CTGF did not show significant difference after Rg3E treatment. Although not statistically significant, (c) 
fibronectin and (d) TGF-β1 showed decreasing trend after the treatment. (e) MMP2 did not show significant 
difference but (f) MMP 9 was significantly decreased. (*P < 0.05. †P = 0.063. ‡P = 0.057. N = 4).
www.nature.com/scientificreports/
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Figure 6. Mouse endometriosis model results. (a) Photographs showing endometriotic implants in mouse 
model fed with vehicle, low dose (0.1 mg/g), and high dose (0.2 mg/g) of Rg3E for 8 weeks. (b) H&E staining 
of the endometriotic implants of each treatment groups (x200 magnification) (c) Comparisons of the size of 
the endometriotic implants according to different treatment dose shows significantly decreasing size as the 
treatment dose increases. (d) Masson’s trichrome staining of endometriotic implants according to different 
treatment dose. (x100 magnification) (e) Comparisons of Masson’s trichrome staining scores according to 
different treatment dose also shows significant decreases as the treatment dose increases. (**P < 0.01. N = 10 
per group).
www.nature.com/scientificreports/
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analyzed (CTGF, fibronectin, Col-1, and TGF-β). Results differed among the control and Rg3E-treated groups, 
as shown by in vitro experiments and in vivo through Masson’s trichrome staining of mouse endometrial lesions. 
Although we discovered the miRNA related to this phenomenon, further studies will be needed to confirm the 
specific mechanism of Rg3′s anti-fibrotic activity.
Recently, several studies have described the relationship between miRNAs and endometriosis pathogenesis. 
A recent study revealed that lower levels of miR-200b, miR-15a-5p, miR-19b-1-5p, miR146a-5p, and miR-200c, 
and higher levels of miR-16-5p, miR-106b-5p, and miR-145-5p are related to modulation of vascular endothe-
lial growth factor A (VEGFA), epidermal growth factor receptor 2 (EGFR2), phosphatase and tensin homolog 
(PTEN), and C-X-C chemokine receptor type 4 (CXCR4) expression, which are important in the pathogenesis 
of endometriosis37. Another study showed that miR-503, a miRNA that is repressed in endometriosis, induces 
apoptosis and inhibits cell proliferation, angiogenesis, and contractility of human ovarian endometriotic stromal 
cells38.
Figure 7. In vivo mRNA concentrations of MMP2, MMP9, CTGF, Col-1, fibronectin, and TGF-β1 after Rg3E 
treatment for 8 weeks. Quantitative RT-PCR amplification was performed using the 7300 Real Time PCR 
System (Applied Biosystems, Foster City, CA, USA). The mRNA concentrations of each sample were normalized 
to GAPDH expression. The invasion markers, (a) MMP2 and (b) MMP9, and fibrosis markers, (c) CTGF (d) 
Col-1 (e) fibronectin and (f) TGF-β1, all decreased significantly for mouse with 8-weeks of Rg3E treatment 
compared to control mice. (*P < 0.05. **P < 0.01. N = 5).
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Among the miRNAs examined in this study, miR-27b was particularly highly expressed in the endometrium 
of patients with endometriosis. Several previous studies suggest that miR-27b is involved in fibrosis develop-
ment. Overexpression of miR-27b promotes hypertrophic cardiomyocyte growth, while its suppression leads to 
inhibition of hypertrophic cell growth39. miR-27b expression significantly increased in both the sclerotic intima 
and serum samples of arteriosclerosis obliterans patients40. In pulmonary fibrosis, overexpression of miR-27b 
increased the expression of alpha smooth muscle actin (α-SMA)41. All these studies have shown that miR-27b 
expression is induced by TGF-β1, which is also related to fibrosis. Although there were some discrepancies in 
results from PCR and transfection in this study, we speculate that Rg3 affects various types of miRNAs simultane-
ously to inhibit fibrosis. The transfection experiment was specifically proceeded with miR-27b-3p inhibitor that 
other fibrosis markers which were not significantly changed may be regulated mainly by other types of miRNAs. 
Therefore, increased expression of miR-27b in endometriosis may be related to its fibrotic characteristics. More 
importantly, decreased miR-27b by Rg3E treatment demonstrates that Rg3 may be effective for reducing the 
fibrotic nature of the disease.
In conclusion, Rg3 is shown to have beneficial effects for reducing the proliferative, invasive, and fibrotic 
nature of endometriosis. Among the endometriosis-affected miRNAs, miR-27b-3p was especially related to the 
development of fibrosis and inhibition of miR-27b significantly reduced fibrosis. In addition, Rg3 downregulated 
miR-27b-3p expression in HESCs. Therefore, Rg3 and modulation of associated miRNAs may be an adjuvant 
therapy for endometriosis.
Subjects and Methods
Study Population and Sample Collection. Thirty-six Korean female patients aged from 21–49 (premen-
opausal women) were enrolled in this study, and written informed consent was obtained before surgery in accord-
ance with the study protocol, which was approved by the Institutional Review Board of Gangnam Severance 
Hospital. Patients included in this study underwent laparoscopy for endometriosis or other benign ovarian cysts. 
Twenty-one patients were histologically confirmed to have endometriosis. Fifteen patients with histologically 
confirmed other benign ovarian cysts were included as controls. Postmenopausal women, previous hormone or 
GnRH agonist users, and patients who had adenomyosis, endometrial cancer, endometrial hyperplasia or endo-
metrial polyps, infectious diseases, chronic or acute inflammatory diseases, malignancy, autoimmune diseases, 
or cardiovascular diseases were excluded.
Culture of Primary Endometrial Stromal Cells and Ishikawa Cell Line. Eutopic endometrial 
tissue was obtained from 21 patients with endometriosis and 15 patients with benign ovarian cysts by endo-
metrial biopsy before surgical procedures. Most of the endometrial tissue samples were obtained at secretory 
phase and very few were at proliferative phase. The phase of the cycle was confirmed by calculating the 
menstrual cycle date. The tissue samples were minced into smaller pieces and incubated in Hank’s balanced 
salt solution including HEPES (25 mmol/mL), 1% penicillin/streptomycin, collagenase (1 mg/mL, 15 U/
mg), and deoxyribonuclease (0.1 mg/mL, 1,500 U/mg) for 60 min at 37 °C with agitation and pipetting. The 
cells were pelleted, washed, suspended in Ham F12:DMEM (1:1) containing 10% fetal bovine serum (FBS) 
and 1% penicillin/streptomycin and then passed through a 40-µm cell strainer (Falcon) and plated into 
75 cm2 Falcon tissue culture flasks (BD Biosciences, San Jose, CA, USA). Cultured HESCs at 3–5 passages 
were used for further analysis. Ishikawa cells were maintained in MEM (Invitrogen, Carlsbad, CA, USA) 
containing 2.0 mmol/L l-glutamine and Earl salts and supplemented with 10% FBS, 1% sodium pyruvate, 
and 1% penicillin/streptomycin42.
Cell viability assay. Cytotoxicity was measured using the TACS® MTT cell proliferation assay kit (Trevigen, 
Gaithersburg, MD, USA). Cells were seeded onto 96-well plates and treated with indicated concentrations of sap-
onin for 48 h. Post treatment, MTT (10 µL per well) was added, and the plates were incubated at 37 °C. Dimethyl 
sulfoxide (DMSO, 100 µL) was added, and the dark blue formazan product was quantified using a microplate 
reader at 570 nm (with a 690 nm reference filter) (Molecular Device, Sunnyvale, CA, USA). Relative cell viability 
(%) is expressed as a percentage relative to non-treated control cells43.
Rg3E treatment. Rg3E powder was provided by Korea Ginseng Corporation. 1 g of Rg3E powder was 
diluted in 1 ml of PBS by vortexing, keeping it in the water bath (37 °C) for 30 minutes to 1 hour, and then on 
a shaker for 20–30 minutes. The first filtration was done with 0.8 μm filters, and 0.2 μm filters were used for the 
second filtration of Rg3E44,45.
HESCs from patients with endometriosis and Ishikawa cells were harvested from culture flasks using trypsin/
EDTA (0.05%) and plated in 6-well plates (200 mL media) at 37 °C with 95% air and 5% CO2 in a humidified 
environment. HESCs were grown in Ham F12/DMEM (1:1) containing 10% FBS and 1% penicillin/streptomycin. 
Ishikawa cells were grown in MEM (Invitrogen) containing 2.0 mmol/L l-glutamine and Earl salts supplemented 
with 10% FBS, 1% sodium pyruvate, and 1% penicillin/streptomycin. At 80% confluency, Rg3E was added at 
concentrations of 0 µL/mL and 400 µL/mL per the MTT assay results and cultured for 48 h.
RNA Extraction and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). To assess 
mRNA concentrations, total RNA was extracted from cultured cells with Qiagen RNeasy isolation kit (Qiagen, 
Hilden, Germany). The specific method for acquiring mRNA is described in the Supplementary Information. The 
mRNA levels of each sample were normalized to GAPDH expression42,43,46–48.
To assess miRNA expression levels, RNA was extracted from cultured cells using the miRVana RNA Isolation 
Kit (Ambion by Life Technologies, Carlsbad, CA, USA) per the manufacturer’s specifications and eluted with 
30 µL nuclease-free water. Isolated RNA (10 ng) and Taqman MicroRNA Reverse Transcription Kit (Applied 
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Biosystems by Thermo Fisher Scientific, Baltics, UAB, Lithuania) were used. Quantitative real-time PCR for miR-
NAs was performed using a Taqman® Universal Master Mix II, no UNG (Applied Biosystems, Foster City, CA, 
USA) with sets for miR-27b-3p and U6 snRNA (Applied Biosystems, Foster City, CA, USA). All real-time PCR 
reactions were conducted in triplicate with a 7300 real time PCR system, and 40 cycles of amplification were per-
formed. Relative expressions were calculated using the comparative threshold cycle method, and miRNA levels 
were normalized to U6 levels42. Relative miRNA levels were determined using the formula 2−ΔCt. Primers used in 
this experiment are described in the Supplementary Information.
Migration Assay. The migration assay for transfected cultured cells was carried out using 8-mm pore size 
polycarbonate membranes (Millipore, Billerica, MA, USA) and 24-well plates. Freshly trypsinized and washed 
cells were suspended in serum-free medium, and cells (200 mL, 5 × 104 cells/well) were placed in the top chamber 
of each insert; medium (600 mL) containing 10% FBS was added into the lower chambers. After incubating for 
24 h at 37 °C in a 5% CO2 humidified incubator, cells were fixed and stained with hematoxylin. Cells in the inner 
chamber were removed with the use of a cotton swab, and cells attached to the bottom side of the membrane were 
counted and imaged under an inverted microscope (Olympus Corp., Shinjuku, Tokyo, Japan) at 200 × magnifi-
cation over ten random fields in each well42.
Collagen Gel Contraction Assay. A sterile solution of bovine Type I Collagen (Cell Biolabs, Inc., San 
Diego, USA) was prepared per the manufacturer’s instructions. HESCs from the endometrium of the patients 
with endometriosis treated with Rg3E for 48 h were embedded in collagen gel and cultured three-dimensionally. 
Briefly, HESCs were suspended in the collagen solution (3.0 × 105 cells/mL). The collagen/cell mixture (2 mL/
plate) was dispensed into 35-mm culture plates (Corning, New York, NY, USA); the mixture was polymerized at 
37 °C for 1 hour. Immediately after polymerization, 1 mL culture medium was added to each plate. After incubat-
ing for 72 h, the collagen gels were photographed and the gel surface area was measured49,50.
miRNA Microarray Analysis. For quality control, RNA purity and integrity were evaluated using an OD 
260/280 ratio and analyzed with ND-1000 Spectrophotometer (NanoDrop, Wilmington, USA) and Agilent 2100 
Bioanalyzer (Agilent Technologies, Palo Alto, USA). The Affymetrix GeneChip® miRNA array process was con-
ducted per the manufacturer’s protocol. 1 µg RNA samples were labeled with the FlashTag™ Biotin RNA Labeling 
Kit (Genisphere, Hatfield, PA, USA). The labeled RNA was quantified, fractionated and hybridized to the miRNA 
microarray according to the standard procedures provided by the manufacturer. The labeled RNA was heated to 
99 °C for 5 minutes and then to 45 °C for 5 minutes. RNA-array hybridization was performed with agitation at 
60 rotations per minute for 16–18 hours at 48 °C on an Affymetrix® 450 Fluidics Station. The chips were washed 
and stained using a Genechip Fluidics Station 450 (Affymetrix, Santa Clara, California, United States). The chips 
were then scanned with an Affymetrix GeneChip Scanner 3000 (Affymetrix, Santa Clara, California, United 
States). Signal values were computed using the Affymetrix® GeneChip™ Command Console software. Raw data 
were extracted automatically in Affymetrix data extraction protocol using the software provided by Affymetrix 
GeneChip® Command Console® Software (AGCC). The CEL files import, miRNA level RMA + DABG-All anal-
ysis and result export were done using Affymetrix® Expression Console™ Software. Array data were filtered by 
probes annotated species.
The comparative analysis between test sample and control sample was carried out using independent t-test 
and fold change in which the null hypothesis was that no difference exists among groups51–54. False discovery rate 
(FDR) was controlled by adjusting P-value using Benjamini-Hochberg algorithm. All statistical tests and visual-
ization of differentially expressed genes were conducted using R statistical language 3.1.2. (www.r-project.org).
Transfection of miRNA. Cells were cultured to 70–80% confluence after being seeded onto 6-well plates 
and were transfected with hsa-mir-27b-3p inhibitor, a chemically synthesized double-stranded RNA that inhibits 
mature endogenous miRNA, or hsa-mir-negative as a control (Ambion by Life Technologies) with the use of 
Lipofectamine 2000 (Invitrogen) per the manufacturer’s instructions, at a final concentration of 50 nmol/L. The 
transfected cells were harvested 48 h after transfection42.
Western blot. The protein extracts were prepared using RIPA buffer (Thermo Scientific, Rockford, IL, USA) 
containing freshly added protease and phosphatase inhibitor cocktail (Thermo Scientific). The concentrations of 
total cell lysates were measured using a BCA protein assay kit (Thermo Scientific). A total of 20 µg total protein 
was mixed with 5X sample buffer and heated at 95 °C for 5 min. The samples were loaded onto 8–12% sodium 
dodecyl sulfate-polyacrylamide gels (SDS-PAGE) and electrotransferred to a polyvinylidene fluoride membrane 
(Millipore Corporation, Billerica, MA, USA) using a Transblot apparatus (Bio-Rad). The membranes (Millipore 
Corporation, USA) were blocked using 5% non-fat skim milk in Tris-buffered saline solution (10 mmol/L 
Tris-HCl (pH 7.4) and 0.5 mol/L NaCl) and adding Tween-20 (0.1% vol/vol).
The blots were probed using primary antibodies: Col-1 (1:1000, Santa Cruz biotechnology), CTGF (1:1000, 
Santa Cruz biotechnology), Fibronectin (1:1000, Santa Cruz biotechnology), TGF-β1 (1:1000, Santa Cruz bio-
technology), MMP2 (1:500, Santa Cruz biotechonology), MMP9 (1:500, Santa Cruz biotechnology) and β-actin 
(1:1000, Abcam, Cambridge, UK), followed by horseradish peroxidase conjugated secondary anti-mouse or 
anti-rabbit antibody (1:2000; Thermo Scientific). The proteins were detected using enhanced chemiluminescence 
(Santa Cruz Biotechnology, Dallas, TX, USA). The experiment was repeated three times for analysis55.
Mouse Model for Endometriosis. The female mouse model for endometriosis was prepared using 
6-week-old C57bl6 female mice as previously described56. This study was approved by the institutional commit-
tee on animal care and was conducted in accordance with its accepted standards. In brief, the donor mouse was 
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sacrificed under anesthetic overdose and its uterus was obtained. The “Y” shaped uterus was cut in half, and then 
each uterine horn was dissected so that the endometrium was exposed. The recipient mouse was anesthetized 
and each uterine horn was transplanted onto each lateral side of the recipient’s peritoneum by vicryl 3-0 sutures. 
The peritoneum and skin were closed with vicryl 3-0 and staplers, and the postoperative condition of the mice 
was checked. Rg3E was diluted in PBS as mentioned previously. Rg3E-treated mice were divided into two groups: 
a high-dose and a low-dose group. There were 10 mice in each group. The high-dose group was given 0.2 mg/g 
Rg3E and the low-dose group was given 0.1 mg/g Rg3E by oral gavage daily, once a day; the control group was 
given an equivalent amount of distilled water, also by oral gavage. The Rg3E treatment was started one day after 
the transplantation date and the total feeding period was 8 weeks.
After 8 weeks of Rg3E treatment, there was no difference in general appearance of the two groups and they 
were sacrificed for endometriotic tissue retrieval. Endometriotic implants were measured by the length and width 
of each lesion and their averages were considered for final analysis. The implants were collected, fixed in 10% 
formalin-acetic acid, and embedded in paraffin for histopathological examination. Paraffin-embedded tissue sec-
tions were stained with Masson’s trichrome stain. Masson’s trichrome staining detects collagen fibrils that are 
deposited in the matrix29. To quantify severity of fibrosis in stained tissue sections, staining scores were calculated 
by multiplying the percentage of positive cells and staining intensity as previously described29,57. The mRNA 
concentrations of invasion and fibrosis markers were also evaluated for mouse model by qRT-PCR as described 
previously and the primers for mouse study is described in the Supplementary Information.
Statistical Analysis. Data are presented as means ± SEM. Data from the in vitro experiments were 
assessed by Kolmogorov-Smirnov test or Shapiro-Wilk test to evaluate whether they were normally distributed. 
Continuous variables were compared using student’s t-test or Mann-Whitney U test, when appropriate. The 
mouse model study data were analyzed by Wilcoxon signed rank test. SPSS v.23.0 and R statistical language 
v.2.15.0 were used for statistical analyses, and P < 0.05 was considered statistically significant.
Data availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
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